Trilobatin, a flavonoid derived from the sweet tea plant Lithocarpus polystachyus, alleviated allergic airway inflammation in a mouse model of asthma, according to a study published in Molecular Biology Reports. The researchers report that the compound suppressed NLRP3 inflammasome activation and caspase-3-associated apoptotic signaling in lung tissue, pointing to a coordinated multi-target mechanism behind its observed anti-inflammatory effects.
Asthma is a heterogeneous chronic airway disease characterized by persistent inflammation, airway hyperresponsiveness, and airway remodeling, largely driven by type 2 immune responses. Although trilobatin is known to exhibit anti-inflammatory and antioxidant properties, its therapeutic effects and molecular mechanisms in asthma had remained insufficiently elucidated, a gap the new study set out to address.
The team used an integrated approach combining network pharmacology, molecular docking, and experimental validation. Candidate trilobatin targets were identified and intersected with asthma-associated genes to construct a protein–protein interaction network, which was then subjected to functional enrichment analyses. Molecular docking highlighted caspase-3 (CASP3) and matrix metalloproteinase-9 (MMP9) as potential key targets, both showing favorable binding affinities to the compound in the computational models.
These computational predictions were then tested in a house dust mite-induced murine model of asthma. Treatment with trilobatin alleviated airway inflammation and reduced the production of proinflammatory cytokines. Mechanistic analyses of lung tissue further indicated that the compound inhibited NLRP3 inflammasome activation and CASP3-associated apoptotic signaling, consistent with the targets flagged by the docking analyses.
The authors conclude that trilobatin alleviates allergic airway inflammation in experimental asthma, potentially through the coordinated regulation of NLRP3 inflammasome activation and caspase-3-associated apoptotic signaling. They suggest the findings provide mechanistic insight into the compound’s anti-asthmatic effects and support its further investigation as a potential therapeutic candidate for asthma.
The findings are limited to preclinical experimental models. The study was conducted in mice, and the reported effects on cytokine production, inflammasome activation, and apoptotic signaling were measured in lung tissue within that model. The authors describe the work as supporting further investigation rather than establishing clinical efficacy, and no human data are reported in the study.
Subject of Research: Trilobatin's effects on allergic airway inflammation in a mouse model of asthma
Article Title: Trilobatin attenuates allergic airway inflammation via multi-target suppression of NLRP3 inflammasome activation and caspase-3 signaling
Article References: Fang, S., Liu, W., Ouyang, S., & Chen, J. (2026). Trilobatin attenuates allergic airway inflammation via multi-target suppression of NLRP3 inflammasome activation and caspase-3 signaling. Molecular Biology Reports, 53(1), Article 1810. https://doi.org/10.1007/s11033-026-13021-0
Image Credits: AI Generated
DOI: 10.1007/s11033-026-13021-0
Keywords: asthma, trilobatin, NLRP3 inflammasome, caspase-3, MMP9, network pharmacology, molecular docking, house dust mite, airway inflammation, flavonoid, Lithocarpus polystachyus, mouse model
News Source: Drew Townsend. (October 29, 2026). Sweet Tea Flavonoid Trilobatin Eases Allergic Airway Inflammation in Mice. Scienmag.
